NCT02269423View on ClinicalTrials.gov

Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 13, 2014

Primary Completion Date

August 25, 2015

Study Completion Date

August 25, 2015

Conditions
Ebola Virus
Interventions
BIOLOGICAL

V920

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

OTHER

Placebo

Normal saline placebo.

Sponsors
All Listed Sponsors
collaborator

BioProtection Systems Corporation

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Merck Sharp & Dohme LLC

INDUSTRY